Rabies Vaccine Market – By Product Type [Baby Hamster Kidney (BHK), Vero Cell Rabies Vaccine], Type (Human, Veterinary), Application (Pre-Exposure Prophylaxis, Post Exposure Prophylaxis), Distribution Channel, Global Forecast (2024 – 2032)

Rabies Vaccine Market Size

Rabies Vaccine Market size was valued at USD 1.1 billion in 2023 and is anticipated to witness growth at a CAGR of 4.5% from 2024 and 2032. Increasing awareness about rabies prevention and control, particularly in developing regions where rabies is more prevalent, significantly boosts market demand.
 

Additionally, government initiatives and public health campaigns aimed at eradicating rabies, along with the support of international organizations like the World Health Organization (WHO), also play a crucial role. For instance, WHO and its global partners aim to end human deaths from dog-mediated rabies through a comprehensive One Health approach promoting mass dog vaccination, ensuring access to post exposure prophylaxis, health worker training, improved surveillance, and bite prevention through community awareness. Furthermore, advances in vaccine technology, improving the efficacy and safety of rabies vaccines, further stimulates market growth.
 

A rabies vaccine is a biological preparation that provides active acquired immunity to rabies, a viral disease typically transmitted through the bite of an infected animal. Rabies vaccines are used both for pre-exposure prophylaxis, which is recommended for individuals at high risk of rabies exposure (such as veterinarians, animal handlers, and travelers to high-risk areas), and for post-exposure prophylaxis, which is administered after a potential exposure to the rabies virus to prevent the onset of the disease. The vaccines are crucial in controlling and preventing rabies in both humans and animals.
 

Rabies Vaccine Market Trends

• The increasing incidence of rabies is a significant driver of the market. Despite being preventable, rabies remains a major public health concern in many parts of the world, particularly in Asia and Africa, where access to preventive healthcare and vaccination is limited.
   
• For instance, as per the WHO, rabies is estimated to cause 59,000 human deaths annually in over 150 countries, with 95% of cases occurring in Africa and Asia.
   
• This rising number of reported rabies cases, coupled with increased awareness of the disease's fatal nature, has led to a growing demand for effective vaccination programs.
   
• Moreover, governments and health organizations are intensifying efforts to control rabies through mass vaccination campaigns for both humans and animals, further propelling the market for rabies vaccines.
   

Rabies Vaccine Market Analysis

Based on product type, the market is segmented into Baby Hamster Kidney (BHK), purified chick embryo cell rabies vaccine, Vero cell rabies vaccine, and other product types. The Baby Hamster Kidney (BHK) segment dominated the market in 2023 and accounted for USD 452 million.
 

• The Baby Hamster Kidney (BHK) segment commands a high market share in the market due to its superior cell line efficiency and robustness in vaccine production.
   
• BHK cells are widely recognized for their high yield and consistent quality in producing rabies vaccines, making them a preferred choice among manufacturers. Their capability to grow rapidly and adapt to serum-free media enhances scalability and cost-effectiveness, further boosts its adoption.
   
• Additionally, the established regulatory approvals and extensive research supporting the safety and efficacy of BHK-derived vaccines further solidify their dominant position in the market.

Based on type, the rabies vaccine market is segmented into human and veterinary. The human segment held a market share of 68% in 2023.
 

• The increasing incidence of rabies infections globally coupled with several public health initiatives and government programs aimed at controlling and preventing rabies drives demand for human rabies vaccines.
   
• Additionally, heightened awareness about the fatal consequences of rabies and the importance of post-exposure prophylaxis among populations in high-risk regions contribute significantly.
   
• Furthermore, international organizations like the World Health Organization (WHO) and various non-governmental organizations (NGOs) play a pivotal role in vaccination campaigns, particularly in endemic areas, ensuring widespread vaccine accessibility and administration to people, thereby contributing to the high segmental growth.
   

Based on application, the rabies vaccine market is segmented into pre-exposure prophylaxis and post exposure prophylaxis. The post exposure prophylaxis segment is anticipated to grow at a CAGR of 4.2% between 2024 - 2032.
 

• Post exposure prophylaxis plays a critical role in preventing the onset of rabies after exposure to the virus, driving demand globally.
   
• Increased awareness of rabies and its prevention, coupled with governmental and non-governmental initiatives to control and eradicate the disease, have further propelled the adoption of post exposure prophylaxis vaccination.
   
• Additionally, the efficacy of PEP in managing rabies cases make it a cornerstone of rabies control strategies, reinforcing its dominant position in the market.
   

Based on distribution channel, the rabies vaccine market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated the market in 2023 and is anticipated to reach USD 854.3 million by 2032.
 

• Hospitals are primary care centers for rabies exposure, especially in cases requiring immediate post-exposure prophylaxis (PEP). This urgency for prompt medical intervention drives high demand for rabies vaccines within hospital pharmacies, ensuring they are readily available for both immediate administration and scheduled follow-up doses.
   
• Furthermore, hospitals often serve as centralized hubs for large-scale vaccination programs, contributing to their substantial share in the market. Thus, the integrated healthcare services provided by hospitals, including comprehensive diagnostic and therapeutic facilities, further enhance the accessibility and reliability of rabies vaccination, thereby solidifying the hospital pharmacy segment's dominance in the market.

North America rabies vaccine market was valued at USD 445.1 million in 2023 and is anticipated to reach USD 635.7 million by 2032.
 

• The region's robust healthcare infrastructure and high awareness of rabies prevention contribute to the widespread adoption of rabies vaccines.
   
• Additionally, the presence of leading pharmaceutical companies and strong government initiatives for rabies control and prevention further bolster market growth.
   
• Moreover, the increasing incidence of rabies in wildlife and domestic animals necessitates the continuous demand for effective vaccines, solidifying North America's dominance in the global market.
   

The U.S. rabies vaccine market is anticipated to grow at a CAGR of 4% between 2024 - 2032.
 

• The country's robust vaccination programs contribute significantly to this dominant position.
   
• Additionally, strong support from governmental and non-governmental organizations for rabies control and prevention initiatives bolsters market growth.
   
• Moreover, the presence of major pharmaceutical companies and continuous advancements in vaccine research and development further enhance the U.S. market.
   

UK is anticipated to witness robust growth in the global rabies vaccine market.
 

• The country's robust healthcare infrastructure and high standards of medical practice ensure widespread access to vaccines, bolstering public health initiatives aimed at controlling rabies.
   
• Additionally, increasing awareness about rabies prevention, particularly through vaccination, has led to greater demand for both pre-exposure and post-exposure prophylaxis.
   
• Further, Germany's strong research and development capabilities have facilitated the development of advanced rabies vaccines, including those with enhanced safety profiles and efficacy, thereby enhancing the market growth in the country.
   

India rabies vaccine market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country's increasing population, coupled with a rising awareness of the importance of rabies prevention, has led to a higher demand for vaccines.
   
• Further, government initiatives aimed at expanding immunization programs and improving healthcare infrastructure have also played a significant role in driving market growth.
   
• Additionally, the presence of several vaccine manufacturers in India has contributed to the country's dominance in the market, with locally produced vaccines being cost-effective and widely accessible.
   

Rabies Vaccine Market Share

The market is characterized by a highly competitive landscape with several key players vying for market share. Companies such as Sanofi, GlaxoSmithKline, and Merck & Co. are among the prominent players in the market, offering a range of rabies vaccines for both human and animal use. These companies focus on research and development to enhance the efficacy and safety profiles of their vaccines, as well as on expanding their geographical presence through strategic partnerships and collaborations.
 

Additionally, the market is witnessing the entry of new players, especially in emerging economies, which is intensifying competition. Factors such as increasing awareness about rabies prevention, government initiatives for vaccination programs, and rising incidences of rabies cases globally are driving the growth of the market, further fuelling competition among key players.
 

Rabies Vaccine Market Companies

Prominent players operating in the rabies vaccine industry include:

• Bavarian Nordic A/S
• Bharat Biotech International Limited
• Bio-Manguinhos/Fiocruz
• Cadila Pharmaceuticals
• China National Biotec Group Co.
• Elanco Animal Health Incorporated
• GSK plc.
• Indian Immunologicals Ltd.
• Liaoning Chengda Biological
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Serum Institute of India Pvt. Ltd
• Virbac
• Zoetis Inc.
   

Rabies Vaccine Industry News:

• In April 2024, Sanofi announced the launch of Verorab (Sanofi inactivated rabies vaccine) in UK. Verorab is an inactivated rabies vaccine indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups. This helped the company expand its sales in Europe.
   
• In April 2022, Cadila Pharmaceuticals launched a three-dose recombinant nanoparticle-based G protein rabies vaccine in Ahmedabad. This is a three-dose regimen to be given over a period of one week (on day 0, day three, and day seven) after exposure to the virus. It is the first in a long list of existing rabies vaccines that require five doses. This helped the company expand its product offerings.
   

The rabies vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Baby Hamster Kidney (BHK)
• Purified chick embryo cell rabies vaccine
• Vero cell rabies vaccine
• Other product types

Market, By Type

• Human
• Veterinary

Market, By Application

• Pre exposure prophylaxis
• Post exposure prophylaxis

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa